Status:

COMPLETED

Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7)

Lead Sponsor:

Nobelpharma

Conditions:

Qt Interval, Variation in

Eligibility:

All Genders

20-45 years

Phase:

PHASE1

Brief Summary

A study to assess the QTc prolongation effect of NPC-15 (melatonin 8mg or 16mg)

Detailed Description

This study is a single center, open label, dose escalation trial to evaluate prolongation effect on QT interval of NPC-15 (melatonin 8mg or 16mg). The trial compose of 3 periods; During the each peri...

Eligibility Criteria

Inclusion

  • Subject with BMI ≥ 17.6 kg/m2 and \< 30.0 kg/m2.
  • Subject who falls asleep at between 21:00 and 25:00 and wakes up at between 5:00 and 9:00 during 1 week prior to the first study drug administration.
  • Subject who is able to comply with the study requirements during the study period.

Exclusion

  • Subject with QTcF interval greater than 450 ms in male or greater than 470 ms in female on the 12-lead electrocardiogram (ECG), or with clinically significant ECG abnormalities in other findings.
  • Subject who has a family history of Torsades de Pointes (TdP) or long QT syndrome.
  • Subject who has a history of hypersensitivity or allergies to melatonin or ramelteon.
  • Subject who has a current or a history of disease which is considered inappropriate to be involved in the study, or who has any current disease to require treatments.
  • Subject who received any non-prescription or prescription drug within 2 weeks prior to the first study drug administration.
  • Subject who received any product containing St Jones Wart or any supplement containing melatonin within 4 weeks prior to the first study drug administration.
  • Subject who has a history of smoking habit or was possibly exposed to passive smoking on a daily basis within 24 weeks prior to the first study drug administration.
  • Subject who, in the opinion of the investigator or sub-investigator, is unsuitable to be involved in the study.

Key Trial Info

Start Date :

April 3 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 29 2018

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT03475459

Start Date

April 3 2018

End Date

April 29 2018

Last Update

June 28 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

SOUSEIKAI Hakata Clinic

Fukuoka, Japan, 8120025